Hemispherx Biopharma (HEB) Receives ANMAT Approval for Commercial Sale of Rintatolimod in Argentine Republic
Go back to Hemispherx Biopharma (HEB) Receives ANMAT Approval for Commercial Sale of Rintatolimod in Argentine Republic| HEMISPHERX BIOPHARMA, Inc. (NYSE: HEB) | Delayed: 1.80 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.80 | 52 Week High | $1.48 | |||
| Open | $1.46 | 52 Week Low | $0.06 | |||
| Day High | $1.80 | P/E | N/A | |||
| Day Low | $1.80 | EPS | $-0.11 | |||
| Volume | 94,971 | |||||
